Abstract
Background/Aims. The aim of this study was to investigate the diagnostic role of CSF β-amyloid(1-42) levels and auditory event-related potentials (AERPs) in the progression of mild cognitive impairment (MCI) to Alzheimers disease (AD). Methods. In fifty three MCI patients (group 1) a lumbar puncture was performed and β-amyloid(1-42) levels were determined. Twenty patients (group 2) were re-examined after 11 months. During this period five of them progressed to AD. Neuropsychological and ERP examinations were performed in all patients at both exams. Results. Compared to MCI-stable patients, AD-converters showed significantly lower β-amyloid(1-42) values both for group 1 (Mann Whitney test, Z=-2.952, p=0.003; effect size r=-0.41) and group 2 (Z=-2.458, p=0.011; effect size r=- 0.55). On the other hand, the patients of group 1 who converted to AD had prolonged latencies and lower amplitudes of the P300 wave compared to those of the MCI-stable patients, although the differences were not significant. Conclusions. Compared to the separate use of CSF β-amyloid(1-42) and AERPs, higher values of sensitivity and specificity were achieved by the combined use of β-amyloid(1-42) levels and P300 latencies (80% and 98%) or amplitudes (100% and 89%) in the discrimination between AD-converters and MCI-stable patients. Therefore the combination of an electrophysiological and a biological marker is potentially of high diagnostic value for the early diagnosis of AD-converters.
Keywords: Mild cognitive impairment, Alzheimer's disease, β-amyloid(1-42), auditory event-related potentials, P300 latency, P300 amplitude
Current Alzheimer Research
Title: Combination of P300 and CSF β-Amyloid(1-42) Assays May Provide a Potential Tool in the Early Diagnosis of Alzheimers Disease
Volume: 7 Issue: 4
Author(s): V.T. Papaliagkas, G. Anogianakis, M.N. Tsolaki, G. Koliakos and V.K. Kimiskidis
Affiliation:
Keywords: Mild cognitive impairment, Alzheimer's disease, β-amyloid(1-42), auditory event-related potentials, P300 latency, P300 amplitude
Abstract: Background/Aims. The aim of this study was to investigate the diagnostic role of CSF β-amyloid(1-42) levels and auditory event-related potentials (AERPs) in the progression of mild cognitive impairment (MCI) to Alzheimers disease (AD). Methods. In fifty three MCI patients (group 1) a lumbar puncture was performed and β-amyloid(1-42) levels were determined. Twenty patients (group 2) were re-examined after 11 months. During this period five of them progressed to AD. Neuropsychological and ERP examinations were performed in all patients at both exams. Results. Compared to MCI-stable patients, AD-converters showed significantly lower β-amyloid(1-42) values both for group 1 (Mann Whitney test, Z=-2.952, p=0.003; effect size r=-0.41) and group 2 (Z=-2.458, p=0.011; effect size r=- 0.55). On the other hand, the patients of group 1 who converted to AD had prolonged latencies and lower amplitudes of the P300 wave compared to those of the MCI-stable patients, although the differences were not significant. Conclusions. Compared to the separate use of CSF β-amyloid(1-42) and AERPs, higher values of sensitivity and specificity were achieved by the combined use of β-amyloid(1-42) levels and P300 latencies (80% and 98%) or amplitudes (100% and 89%) in the discrimination between AD-converters and MCI-stable patients. Therefore the combination of an electrophysiological and a biological marker is potentially of high diagnostic value for the early diagnosis of AD-converters.
Export Options
About this article
Cite this article as:
Papaliagkas V.T., Anogianakis G., Tsolaki M.N., Koliakos G. and Kimiskidis V.K., Combination of P300 and CSF β-Amyloid(1-42) Assays May Provide a Potential Tool in the Early Diagnosis of Alzheimers Disease, Current Alzheimer Research 2010; 7 (4) . https://dx.doi.org/10.2174/156720510791162421
DOI https://dx.doi.org/10.2174/156720510791162421 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Oxidative Stress in Depressive Disorders
Current Pharmaceutical Design HIV-1 TAR RNA: The Target of Molecular Interactions Between the Virus and its Host
Current HIV Research Cognitive Function and Heart Failure: The Role of the Adrenergic System
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Human Umbilical Cord Stem Cell Xenografts Improve Cognitive Decline and Reduce the Amyloid Burden in a Mouse Model of Alzheimer's Disease
Current Alzheimer Research Advanced Diabetes Care: Three Levels of Prediction, Prevention & Personalized Treatment
Current Diabetes Reviews Up-Regulation of Hypoxia-Inducible Factor (HIF)-1α and HIF-Target Genes in Cortical Neurons by the Novel Multifunctional Iron Chelator Anti-Alzheimer Drug, M30
Current Alzheimer Research Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression
Recent Patents on CNS Drug Discovery (Discontinued) “The Future Magic Bullet”: A Review of Pharmacological Activities of Ethyl Pyruvate and its Derivatives
Current Drug Therapy Modulation of Amyloid β Peptide1-42 Cytotoxicity and Aggregation in Vitro by Glucose and Chondroitin Sulfate
Current Alzheimer Research Errors in ADAS-Cog Administration and Scoring May Undermine Clinical Trials Results
Current Alzheimer Research Therapeutic Application of Intrabodies Against Age-Related Neurodegenerative Disorders
Current Pharmaceutical Design Thrombomodulin – A New Target for Treating Stroke at the Crossroad of Coagulation and Inflammation
Current Medicinal Chemistry The Small Heat Shock Protein HspB8: Role in Nervous System Physiology and Pathology
CNS & Neurological Disorders - Drug Targets Pharmacological Approaches to Chronic Spinal Cord Injury
Current Pharmaceutical Design Mediterranean Diet and Low-grade Subclinical Inflammation: The Moli-sani Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases
CNS & Neurological Disorders - Drug Targets Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Melatonin as Antioxidant Under Pathological Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Drug-Related Decrease in Neuropsychological Functions of Abstinent Drug Users
Current Drug Abuse Reviews Design, Synthesis and Evaluation of Tacrine Based Acetylcholinesterase Inhibitors
Letters in Drug Design & Discovery